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Abstract	This pilot study aimed to assess the feasibility of precisely measuring tumor diameter and myometrial
invasion in patients with endometrioid endometrial cancer (EEC) using preoperative contrastenhanced magnetic resonance imaging (MRI). Adult patients with confirmed diagnosis of complex
hyperplasia with atypia or EEC were included. Three radiologists separately measured tumor diameter
and myometrial invasion. Basic descriptive statistics were used to describe patient characteristics
and to compare radiology- and pathology-measured tumor diameter and myometrial invasion. Using
the pathology results for tumor diameter as the gold standard for comparison, at least 1 radiologist
was able to predict largest tumor diameter within 5 mm for 41.7% of patients. Similarly, based
on pathology results for myometrial invasion, at least 1 radiologist was able to predict myometrial
invasion within 5% for 50% of patients. All radiologists were able to predict superficial (<50%) or deep
(≥50%) myometrial invasion for 75% of patients, with greater sensitivity, specificity, and accuracy
for deep myometrial invasion. Given variation among radiologic measurements, it is difficult to
recommend preoperative MRI as a basis for measuring tumor diameter and myometrial invasion.
Even so, the ability to predict superficial versus deep myometrial invasion may benefit patients with
EEC for whom surgery is not a viable option or for those seeking fertility-sparing treatment options.
(J Patient Cent Res Rev. 2020;7:206-212.)
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I

n the United States, endometrial cancer is the most
common gynecologic cancer and is one of the
few cancers in which incidence is increasing.1-3
According to the American Cancer Society, more than
65,000 new cases of endometrial cancer and uterine
sarcomas will be diagnosed in 2020, and more than
12,000 women will die from the disease.1 While there
are other risk factors for developing endometrial cancer,
unopposed estrogen is the main factor associated with
disease.4,5 This can be secondary to the increasing
incidence of obesity, in which obese women have
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higher levels of endogenous estrogen.4,5 Approximately
5% of patients diagnosed with endometrial carcinoma
or atypical hyperplasia are under the age of 40,6
with findings from Gonthier et al concluding that
younger patients are significantly more likely to be
obese.5 As obesity increases among younger patient
populations, more focus is moving toward fertilitysparing treatments for both atypical hyperplasia of the
endometrium (a precursor of endometrial cancer) and
endometrial cancer itself.5
Currently, hysterectomy and lymphadenectomy
are recommended for patients with endometrioid
endometrial cancer (EEC) who are at greater than low
risk of lymphatic dissemination, with hysterectomy
only recommended for patients at low risk.2 In recent
years, traditional pelvic with or without paraaortic
Brief Report

lymph node dissection has become controversial given
increased morbidity.7 The Society of Gynecologic
Oncology has identified sentinel lymph node mapping as
a reasonable technique to map the lymphatic system and
identify the first lymphatic drainage for the uterus.7 The
theory, supported by multiple studies, suggests that these
first lymph nodes have a high sensitivity and negative
predictive value.8,9 Even so, lymphocysts, lymphedema,
and neuralgia are still risk factors associated with lymph
node dissection, especially full lymph node dissection.7
Given these risks, and the need for fertility-sparing
treatment options, developing preoperative screening
tools may help determine who should or shouldn’t
undergo lymphadenectomy or hysterectomy.
Our previously published risk schema, as well as risk
schemas from other institutions, used tumor diameter
(TD) and myometrial invasion (MI) to predict lowrisk patients who most likely will not benefit from
lymphadenectomy.2,10-12 Several studies have evaluated
magnetic resonance imaging (MRI) for measuring
MI, describing variable sensitivity (69%–94%),
specificity (57%–86%), and accuracy (66%–90%)
when measuring superficial (<50%) versus deep
(≥50%) invasion.13-16 Some studies have evaluated
contrast-enhanced MRI for measuring TD but not as it
relates to sensitivity, specificity, and accuracy.17-19 We
hypothesized that use of MRI may accurately measure
TD and MI preoperatively and may help with the
identification of low-risk patients.
This pilot study aimed to assess the feasibility of
precisely measuring TD and MI in patients with EEC
using preoperative contrast-enhanced MRI. Ultimately,
we hoped to determine whether preoperative MRI
could be used to save patients from lymphadenectomy
or, among patients for whom surgery is not a viable
option, allow for the recommendation of fertilitysparing mechanisms of therapy.

METHODS

A prospective pilot study of adult patients with confirmed
diagnosis of complex hyperplasia with atypia or EEC
during August 2017 through July 2018 was conducted.
Further inclusion criteria required that patients must be
English-speaking, undergoing hysterectomy with 1 of 2
gynecologic oncologists, eligible for contrast-enhanced
3-tesla MRI scan (eg, no pacemaker or defibrillator),
comfortable undergoing MRI scan with/without oral
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sedation, have less than severely compromised kidney
function (ie, glomerular filtration rate of ≥30 mL/min/
1.73 m2), and able to undergo contrast-enhanced MRI
scan at a single medical center 7 days prior to scheduled
hysterectomy. Patients who presented for their MRI
scan prior to their scheduled hysterectomy were
provided with a $50 gift card. The study was approved
by the local institutional review board.
Following MRI scan, a radiologist checked image
quality to determine potential need for a rescan.
Images were then reviewed by 3 separate radiologists
(with 2–10 years of experience depending on time of
enrollment) to determine TD (recorded in anteriorposterior, medial-lateral, and craniocaudal planes),
depth of invasion (disruption of the junctional zone),
and myometrial thickness (recorded thickness at
an adjacent noninvolved segment). All TD and MI
measurements were recorded in millimeters. Image
quality as well as TD and MI image confidence were
recorded on a scale from 1 to 3 (poor, moderate, excellent)
by all 3 radiologists. Data on time of image acquisition
relative to contrast injection were not collected.
Following hysterectomy, chart review was performed
to determine TD and MI as recorded by pathology.
Basic descriptive statistics including counts,
percentages, and means were used to summarize patient
characteristics and TD and MI measurements. MI was
calculated based on depth of invasion/myometrial
thickness × 100%. The largest TD and MI reported
by pathology for each patient was used as the gold
standard for comparison to determine if radiologic
measurements were within 5 mm for largest TD
(regardless of plane in which measurement was taken)
and within 5% for MI. Additionally, the radiologist’s
ability to predict superficial (<50%) versus deep
(≥50%) MI was examined. Sensitivity, specificity, and
accuracy were calculated per standard formulas for MI.
Given the size of our study population, no P-values
were calculated. All analyses were conducted using
SAS 9.4 (SAS Institute Inc., Cary, NC).

RESULTS

A total of 12 patients were enrolled and underwent
contrast-enhanced preoperative MRI. Patients were
predominately white (91.7%), had mean age of 58.8
years (range: 37.3–70.8 years; only 1 patient was under
40 years old), and had mean body mass index of 35.6
www.aurora.org/jpcrr
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kg/m2. Those enrolled had similar histologic grade
and stage, with 91.7% of patients presenting with
International Federation of Obstetrics and Gynecology
(FIGO) grade 1 tumors and 75.0% of patients presenting
with stage 1a uterine cancer, respectively. On average,
patients received their MRI scan and surgery within
33.3 days and 38.7 days of diagnosis, respectively.
In comparison to the largest pathology-reported TD,
at least 1 radiologist was able to accurately predict
largest TD within 5 mm for 41.7% of patients. While 2
radiologists were able to predict largest TD for 3 patients,
all radiologists were not able to predict largest TD for any
1 patient. One radiologist was able to predict largest TD
within 5 mm for 5 patients. Ultimately, large variability
in measurements existed among radiologists (Figure 1).
Similarly, in comparison to the pathology reported MI,
at least 1 radiologist was able to predict no MI or MI
within 5% for 50% of patients. All radiologists were able
to predict no MI for 1 patient, with 2 radiologists able
to predict MI for 1 patient (Figure 2). All radiologists
were not able to predict MI for any 1 patient. Even
so, all radiologists were able to predict superficial MI
or deep MI for 75% of patients, with a kappa statistic

of 0.65 indicating high interrater agreement (Figure 3).
Use of MRI had greater sensitivity, specificity, and
accuracy when predicting deep MI (Table 1).
Radiologists identified a mean MRI image quality of
2.3 (on 1–3 scale). Overall, radiologists were relatively
confident in TD and MI measurements, expressing a
2.6 and 2.3 level of confidence, respectively.

DISCUSSION

This pilot study aimed to determine if MRI could
precisely measure TD and MI among patients with EEC.
Unfortunately, we identified that all radiologists were
not able to predict largest TD within 5 mm of pathologyreported measurements for any single patient. To our
knowledge, limited studies have evaluated the ability to
precisely measure TD through MRI. A previous study by
Bourgioti et al used preoperative TD measured through
MRI to predict MI, suggesting that larger TD is associated
with greater odds of deep MI that may potentially require
surgical management.19 Ytre-Hauge and colleagues also
correlated greater anteroposterior TD with deep MI,
finding low interobserver variability (0.78–0.85) for
all TD measurements.17 However, we observed large
variability among our radiologists, as is seen in Figure 1.

Figure 1. Prediction of largest tumor diameter within 5 mm. Largest tumor diameter as determined by pathology

is considered the gold standard (horizontal stripped bar) for each patient. If the radiologist’s largest tumor diameter
measurement was within 5 mm of pathology, their measurement is reported with a diamond above the bar. Note:
Measurements of zero for tumor diameter are recorded as 0.5 mm for graphing purposes.
208 JPCRR • Volume 7, Issue 2 • Spring 2020
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Figure 2. Prediction of myometrial invasion within 5%. Percentage of myometrial invasion as determined by

pathology is considered the gold standard (horizontal stripped bar) for each patient. If the radiologist’s myometrial
invasion measurement was within 5% of pathology, their measurement is reported with a diamond above the bar.
Note: Measurements for no myometrial invasion are recorded as 0.5% for graphing purposes.

Figure 3. Prediction of superficial versus deep myometrial invasion. The dashed target line is at 50% invasion.

Again, pathology-measured myometrial invasion is considered the gold standard (horizontal stripped bar) for each
patient. Kappa statistic for interrater agreement was 0.65.
Brief Report
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Table 1. Sensitivity, Specificity, and Accuracy Among Radiologists in Predicting Myometrial Invasion
Noninvasive

Radiologist #1

Radiologist #2

Radiologist #3

Averagea

Sensitivity
Specificity
Accuracy
<50%

75%
25%
58.3%
Radiologist #1

62.5%
75%
66.7%
Radiologist #2

75%
75%
75%
Radiologist #3

70.8%
58.3%
66.7%
Averagea

Sensitivity
Specificity
Accuracy
≥50%

40%
42.8%
41.7%
Radiologist #1

20%
85.7%
58.3%
Radiologist #2

40%
85.7%
66.7%
Radiologist #3

33.3%
71.4%
55.6%
Averagea

Sensitivity
Specificity
Accuracy

66.7%
88.9%
83.3%

100%
88.9%
91.7%

100%
88.9%
91.7%

88.9%
88.9%
88.9%

a

Represents the average of all three radiologists for sensitivity, specificity, and accuracy.

Our study identified that all radiologists were not
able to predict MI within 5% of pathology-reported
measurements for any single patient. Even so, all
were able to predict superficial versus deep MI as
identified by pathology in 75% of patients, and all
showed greater sensitivity, specificity, and accuracy
when predicting deep MI. In looking for deep MI
with MRI, Husby et al reported only fair interrater
agreement (κ: 0.32),20 whereas our interrater
agreement for deep MI was higher (κ: 0.65).
Previous studies also have explored the ability to
measure superficial versus deep MI through MRI.13-16
A study by Ryoo et al found that 25.8% of patients
had incorrect MI prediction by MRI, with deep MI
patients of increased age and with increased number
of previous deliveries being more likely to have
an incorrect prediction.13 The authors concluded
that precise or accurate assessment of MI through
MRI is difficult to predict and should be cautiously
interpreted and that tumor and patient characteristics
may further impact ability to predict MI.13 Potentially,
such factors also may impact ability to predict
accurate TD. Antonsen et al suggested MRI should
not replace surgical staging but could potentially be
used to rule out deep MI for those who can’t or don’t
want to undergo surgical staging.15
Endometrial cancer is one of the few cancers
with increasing incidence3 and is associated with
increased surgical morbidity and all-cause mortality,
especially among those who are morbidly obese.21,22
As previously identified, obesity is increasing among
210 JPCRR • Volume 7, Issue 2 • Spring 2020

younger women,5 with adipose tissue creating a
hyperestrogen state, thereby putting these women
at increased risk of developing endometrial cancer
earlier in life.21 Thus, more fertility-sparing and
nonsurgical options for endometrial hyperplasia
and endometrial cancer are needed for patients.
Ultimately, while our findings demonstrated that
the ability to precisely measure MI and TD through
MRI was limited, the ability to measure superficial
versus deep MI was evident. Potentially, use of MRI
may guide clinicians on care options among younger
women seeking fertility-sparing or nonsurgical
treatments. Additionally, it may help to guide care
for women who wish to avoid lymphadenectomy.
Further study is warranted.
This pilot had several limitations; one limitation in
and of itself was that the scarcity of prior evidence
limited our ability to solidly recommend MRI for
preoperative risk assessment. While we aimed to
enroll 3 times as many patients, we had difficulties
enrolling (patients didn’t want to undergo additional
test, drive to testing site, etc) and scheduling (eg,
MRI machine was unavailable prior to surgery)
patients. Even so, among the study’s 12 patients, we
saw a large degree of variation among radiologic
measurements that would most likely have existed
regardless of an increased sample size. The
variability in measurements could be due to the
experience level of the participating radiologists
(ie, 2–10 years) and how frequently they read pelvic
MRIs in their daily practice (per our radiologists,
Brief Report

pelvic MRIs are relatively uncommon within our
health system and tend to be read by those with
greater experience).
Previous studies have shown an association with
apparent diffusion coefficient values and endometrial
carcinomas. However, we did not collect these
values.20 Additionally, the majority of patients
within our study were stage 1a, and it is unknown if
radiologic measurement variability would remain in
higher-stage patients. However, by having a similar
patient population, variability among radiologist
measurements should have been minimal. Lastly,
we didn’t determine whether radiologists were able
to predict smaller TD dimensions, as largest TD or
primary TD was used for identifying risk in previous
retrospective studies.2,10,11
Given the variation between radiologic assessments,
it is difficult to recommend preoperative MRI as a
basis for precisely measuring tumor diameter and
myometrial invasion. However, while huge variation
existed in predicting MI within 5%, radiologists
may be able to predict superficial versus deep MI.
Predicting superficial versus deep MI preoperatively
through contrast-enhanced MRI might help providers
better manage endometrioid endometrial cancer in
patients who are not eligible for surgery or are seeking
fertility-sparing treatments.

Patient-Friendly Recap
• Patients with endometrioid endometrial cancer,
a type of uterine cancer, may be candidates
for noninvasive treatment that preserves future
ability to bear children.
• The authors tested whether radiologists were
able to accurately measure tumor size and
gauge patient risk using MRI.
• Given the variation found among radiologic
measurements, it is difficult to recommend
preoperative MRI as a tool for measuring
endometrioid endometrial cancer status.
• Radiologists were better at broadly
distinguishing mild from deep cancerous
invasion, indicating this tool may be useful in
patients opposed to surgical therapy.
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